European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Enfortumab vedotin to be reviewed under accelerated assessment for the treatment of locally advanced or metastatic urothelial cancer
TOKYO and BOTHELL, Wash., March 26, 2021 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, ... Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, enfortumab vedotin, urothelial cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Pharmaceuticals